About Ophthotech Corporation (NASDAQ:OPHT)
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. Its product candidates include Fovista and Zimura. Fovista is designed to target platelet derived growth factor (PDGF) in combination with anti-vascular endothelial growth factor (VEGF) drugs to disrupt the formation of abnormal new blood vessels in wet AMD. Zimura targets complement factor C5, a central component of the complement cascade. The Company has initiated a Phase II/III clinical trial investigating Zimura for treatment of geographic atrophy.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:OPHT
- CUSIP: N/A
- Web: www.ophthotech.com
Capitalization:- Market Cap: $88.06 million
- Outstanding Shares: 35,943,000
Average Prices:- 50 Day Moving Avg: $2.66
- 200 Day Moving Avg: $2.69
- 52 Week Range: $2.24 - $41.43
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.23
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $10.31 million
- Price / Sales: 8.40
- Book Value: ($4.14) per share
- Price / Book: -0.58
Profitability:- EBITDA: ($181,990,000.00)
- Net Margins: -1,866.58%
- Return on Assets: -70.63%
Debt:- Current Ratio: 7.81%
- Quick Ratio: 7.81%
Misc:- Average Volume: 518,642 shs.
- Beta: 1.46
- Short Ratio: 5.92
Frequently Asked Questions for Ophthotech Corporation (NASDAQ:OPHT)
What is Ophthotech Corporation's stock symbol?
Ophthotech Corporation trades on the NASDAQ under the ticker symbol "OPHT."
How were Ophthotech Corporation's earnings last quarter?
Ophthotech Corporation (NASDAQ:OPHT) announced its earnings results on Wednesday, July, 26th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.45. The business had revenue of $1.66 million for the quarter, compared to analysts' expectations of $1.38 million. The business's revenue was down 94.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.85) earnings per share. View Ophthotech Corporation's Earnings History.
When will Ophthotech Corporation make its next earnings announcement?
Where is Ophthotech Corporation's stock going? Where will Ophthotech Corporation's stock price be in 2017?
12 analysts have issued 12-month price targets for Ophthotech Corporation's shares. Their forecasts range from $4.00 to $92.00. On average, they expect Ophthotech Corporation's stock price to reach $47.33 in the next year. View Analyst Ratings for Ophthotech Corporation.
Who are some of Ophthotech Corporation's key competitors?
Some companies that are related to Ophthotech Corporation include Agile Therapeutics (AGRX), Recro Pharma (REPH), Fate Therapeutics (FATE), Summit Therapeutics PLC (SMMT), Vascular Biogenics (VBLT), Synthetic Biologics (SYN), Cempra (CEMP), Dimension Therapeutics (DMTX), Conatus Pharmaceuticals (CNAT), Redhill Biopharma (RDHL), Adverum Biotechnologies (ADVM), XBiotech (XBIT), Verastem (VSTM), Immune Design Corp. (IMDZ), Cellular Biomedicine Group (CBMG), Verona Pharma Plc (VRP), ImmuPharma PLC (IMM) and MaxCyte (MXCT).
Who are Ophthotech Corporation's key executives?
Ophthotech Corporation's management team includes the folowing people:
- David R. Guyer M.D., Executive Chairman of the Board
- Glenn P. Sblendorio, President, Chief Executive Officer
- David Carroll, Chief Financial Officer, Senior Vice President, Treasurer
- Keith Westby, Chief Operating Officer, Senior Vice President
- Barbara A. Wood Esq., Senior Vice President, General Counsel, Secretary
- David E. Redlick, Lead Independent Director
- Axel Bolte, Independent Director
- Thomas Dyrberg M.D., Independent Director
- Michael Jay Ross Ph. D., Independent Director
How do I buy Ophthotech Corporation stock?
Shares of Ophthotech Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ophthotech Corporation's stock price today?
One share of Ophthotech Corporation stock can currently be purchased for approximately $2.41.
MarketBeat Community Rating for Ophthotech Corporation (NASDAQ OPHT)MarketBeat's community ratings are surveys of what our community members think about Ophthotech Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ophthotech Corporation (NASDAQ:OPHT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 12 Hold Ratings |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | $47.33 (1,864.04% upside) |
Consensus Price Target History for Ophthotech Corporation (NASDAQ:OPHT)
Analysts' Ratings History for Ophthotech Corporation (NASDAQ:OPHT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/21/2017 | Stifel Nicolaus | Reiterated Rating | Hold | $4.00 | Low |  |
| 12/13/2016 | Gabelli | Downgrade | Buy -> Hold | | N/A | |
| 12/13/2016 | Morgan Stanley | Downgrade | Overweight -> Equal Weight | | N/A | |
| 12/12/2016 | Goldman Sachs Group Inc | Upgrade | Sell -> Neutral | | N/A | |
| 12/12/2016 | Leerink Swann | Downgrade | Outperform -> Market Perform | | N/A | |
| 12/12/2016 | BTIG Research | Downgrade | Buy -> Neutral | | N/A | |
| 12/12/2016 | Cowen and Company | Downgrade | Outperform -> Market Perform | | N/A | |
| 12/12/2016 | Citigroup Inc. | Downgrade | Buy -> Neutral | | N/A | |
| 12/12/2016 | Barclays PLC | Downgrade | Overweight -> Equal Weight | | N/A | |
| 12/12/2016 | J P Morgan Chase & Co | Downgrade | Overweight -> Neutral | $11.00 | N/A | |
| 12/12/2016 | SunTrust Banks, Inc. | Downgrade | Buy -> Hold | | N/A | |
| 12/12/2016 | Chardan Capital | Downgrade | Buy -> Neutral | $15.00 | N/A | |
| 11/19/2015 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform | $95.00 | N/A | |
(Data available from 10/21/2015 forward)
Earnings History for Ophthotech Corporation (NASDAQ:OPHT)Earnings History by Quarter for Ophthotech Corporation (NASDAQ OPHT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.84) | | | | | N/A | |
| 7/26/2017 | Q2 2017 | ($1.07) | ($0.62) | $1.38 million | $1.66 million | View | N/A | |
| 5/3/2017 | Q1 2017 | ($1.31) | ($1.20) | $1.94 million | $1.66 million | View | Listen | |
| 11/8/2016 | Q316 | ($1.64) | ($1.71) | $6.20 million | $1.67 million | View | Listen | |
| 8/3/2016 | Q216 | ($1.05) | ($0.85) | $18.64 million | $28.20 million | View | Listen | |
| 5/4/2016 | Q116 | ($1.33) | ($1.03) | $7.22 million | $15.70 million | View | Listen | |
| 2/24/2016 | Q415 | ($1.35) | ($1.02) | $7.59 million | $4.78 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.98) | ($1.14) | $11.31 million | $3.40 million | View | N/A | |
| 8/5/2015 | Q215 | ($1.02) | ($1.08) | $2.77 million | $1.60 million | View | N/A | |
| 5/11/2015 | Q115 | ($0.75) | $0.22 | $3.68 million | $41.70 million | View | Listen | |
| 2/23/2015 | Q414 | ($0.57) | ($1.06) | $12.36 million | $1.68 million | View | N/A | |
| 11/11/2014 | Q314 | ($0.62) | $0.31 | $8.02 million | $39.58 million | View | N/A | |
| 8/6/2014 | Q214 | ($0.56) | ($1.57) | $4.31 million | | View | N/A | |
| 5/13/2014 | Q1 | ($0.67) | ($0.64) | | | View | Listen | |
| 2/27/2014 | | ($0.50) | ($0.65) | | | View | N/A | |
| 11/13/2013 | Q313 | ($1.00) | ($10.26) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ophthotech Corporation (NASDAQ:OPHT)2017 EPS Consensus Estimate: ($1.74)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($1.45) | ($1.45) | ($1.45) |
| Q2 2017 | 2 | ($1.19) | ($1.14) | ($1.17) |
| Q3 2017 | 2 | ($1.04) | $4.23 | $1.60 |
| Q4 2017 | 2 | ($0.79) | ($0.65) | ($0.72) |
(Data provided by Zacks Investment Research)
Dividend History for Ophthotech Corporation (NASDAQ:OPHT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ophthotech Corporation (NASDAQ:OPHT)Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 61.40%
Insider Trades by Quarter for Ophthotech Corporation (NASDAQ:OPHT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/5/2017 | Barbara A Wood | SVP | Sell | 5,119 | $2.58 | $13,207.02 | |
| 7/5/2017 | David Francis Carroll | CFO | Sell | 3,284 | $2.58 | $8,472.72 | |
| 7/5/2017 | David R Guyer | Chairman | Sell | 17,678 | $2.58 | $45,609.24 | |
| 7/5/2017 | Glenn Sblendorio | CEO | Sell | 7,828 | $2.58 | $20,196.24 | |
| 6/13/2017 | David E Redlick | Director | Sell | 700 | $2.52 | $1,764.00 | |
| 4/3/2017 | Glenn Sblendorio | CFO | Sell | 7,388 | $3.56 | $26,301.28 | |
| 1/5/2017 | David R Guyer | CEO | Sell | 3,785 | $4.96 | $18,773.60 | |
| 1/5/2017 | Henric Bjorn Bjarke | SVP | Sell | 316 | $4.96 | $1,567.36 | |
| 1/5/2017 | Samir Chandrakant Patel | President | Sell | 3,844 | $4.96 | $19,066.24 | |
| 1/3/2017 | Barbara A Wood | SVP | Sell | 675 | $4.90 | $3,307.50 | |
| 1/3/2017 | David R Guyer | CEO | Sell | 3,484 | $4.90 | $17,071.60 | |
| 1/3/2017 | Samir Chandrakant Patel | President | Sell | 2,999 | $4.90 | $14,695.10 | |
| 12/23/2016 | Barbara A. Wood | SVP | Sell | 746 | $4.92 | $3,670.32 | |
| 12/22/2016 | Glenn Sblendorio | CFO | Sell | 1,079 | $4.85 | $5,233.15 | |
| 12/15/2016 | A/S Novo | Major Shareholder | Sell | 3,610,487 | $4.87 | $17,583,071.69 | |
| 11/1/2016 | David R Guyer | CEO | Sell | 22,060 | $35.61 | $785,556.60 | |
| 10/3/2016 | David R Guyer | CEO | Sell | 22,060 | $44.37 | $978,802.20 | |
| 9/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $55.17 | $1,103,400.00 | |
| 8/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $52.80 | $1,056,000.00 | |
| 8/1/2016 | David R Guyer | CEO | Sell | 24,060 | $64.47 | $1,551,148.20 | |
| 7/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $64.21 | $1,284,200.00 | |
| 7/1/2016 | David R Guyer | CEO | Sell | 24,060 | $52.12 | $1,254,007.20 | |
| 6/30/2016 | Samir Chandrakant Patel | President | Sell | 41,846 | $51.23 | $2,143,770.58 | |
| 6/3/2016 | Axel Bolte | Director | Buy | 3,500 | $56.97 | $199,395.00 | |
| 6/2/2016 | Glenn Sblendorio | CFO | Sell | 671 | $57.20 | $38,381.20 | |
| 6/1/2016 | David R Guyer | CEO | Sell | 30,060 | $52.71 | $1,584,462.60 | |
| 5/31/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $53.32 | $1,066,400.00 | |
| 5/24/2016 | A/S Novo | Major Shareholder | Sell | 1,300,000 | $49.00 | $63,700,000.00 | |
| 5/2/2016 | David R Guyer | CEO | Sell | 22,060 | $46.18 | $1,018,730.80 | |
| 4/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $46.79 | $935,800.00 | |
| 4/1/2016 | David R Guyer | CEO | Sell | 22,060 | $44.11 | $973,066.60 | |
| 3/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $41.85 | $837,000.00 | |
| 3/1/2016 | David R Guyer | CEO | Sell | 22,060 | $45.48 | $1,003,288.80 | |
| 2/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $45.13 | $902,600.00 | |
| 1/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $53.59 | $1,071,800.00 | |
| 1/28/2016 | David R. Guyer | CEO | Sell | 18,598 | $53.63 | $997,410.74 | |
| 1/11/2016 | Nicholas Galakatos | Director | Sell | 3,000 | $65.72 | $197,160.00 | |
| 1/4/2016 | Barbara A. Wood | SVP | Sell | 1,000 | $76.37 | $76,370.00 | |
| 12/30/2015 | David R. Guyer | CEO | Sell | 18,582 | $78.82 | $1,464,633.24 | |
| 12/30/2015 | Glenn Sblendorio | Director | Sell | 2,000 | $80.00 | $160,000.00 | |
| 12/29/2015 | Samir Chandrakant Patel | President | Sell | 1,184 | $77.50 | $91,760.00 | |
| 12/24/2015 | Samir Chandrakant Patel | President | Sell | 26,036 | $77.09 | $2,007,115.24 | |
| 12/10/2015 | Nicholas Galakatos | Director | Sell | 3,000 | $64.44 | $193,320.00 | |
| 12/1/2015 | Barbara A. Wood | SVP | Sell | 2,000 | $63.24 | $126,480.00 | |
| 11/30/2015 | David R. Guyer | CEO | Sell | 18,582 | $62.49 | $1,161,189.18 | |
| 11/24/2015 | Samir Chandrakant Patel | President | Sell | 27,215 | $60.27 | $1,640,248.05 | |
| 11/18/2015 | Nicholas Galakatos | Director | Sell | 1,500 | $60.00 | $90,000.00 | |
| 11/5/2015 | Samir Chandrakant Patel | President | Sell | 20,687 | $53.55 | $1,107,788.85 | |
| 10/21/2015 | Samir Chandrakant Patel | President | Sell | 27,215 | $43.27 | $1,177,593.05 | |
| 10/16/2015 | Barbara A. Wood | SVP | Sell | 2,000 | $45.00 | $90,000.00 | |
| 9/29/2015 | David R. Guyer | CEO | Sell | 18,582 | $37.69 | $700,355.58 | |
| 9/21/2015 | Samir Chandrakant Patel | President | Sell | 27,215 | $46.34 | $1,261,143.10 | |
| 8/31/2015 | David R. Guyer | CEO | Sell | 18,582 | $44.88 | $833,960.16 | |
| 8/20/2015 | Samir Chandrakant Patel | President | Sell | 27,215 | $48.75 | $1,326,731.25 | |
| 7/20/2015 | Samir Chandrakant Patel | President | Sell | 27,215 | $67.87 | $1,847,082.05 | |
| 7/17/2015 | Glenn Sblendorio | Director | Sell | 3,000 | $67.33 | $201,990.00 | |
| 7/1/2015 | Barbara A Wood | SVP | Sell | 2,000 | $51.94 | $103,880.00 | |
| 6/29/2015 | David R Guyer | CEO | Sell | 18,582 | $51.05 | $948,611.10 | |
| 6/18/2015 | Samir Chandrakant Patel | President | Sell | 12,000 | $49.78 | $597,360.00 | |
| 5/28/2015 | David R Guyer | CEO | Sell | 18,582 | $48.62 | $903,456.84 | |
| 4/29/2015 | David R Guyer | CEO | Sell | 18,582 | $48.45 | $900,297.90 | |
| 4/17/2015 | Samir Chandrakant Patel | President | Sell | 12,000 | $50.47 | $605,640.00 | |
| 3/30/2015 | Axel Bolte | Director | Buy | 500 | $48.27 | $24,135.00 | |
| 3/30/2015 | David R Guyer | CEO | Sell | 18,582 | $48.26 | $896,767.32 | |
| 3/2/2015 | Barbara A Wood | SVP | Sell | 2,000 | $53.26 | $106,520.00 | |
| 3/2/2015 | David R Guyer | CEO | Sell | 18,582 | $53.22 | $988,934.04 | |
| 1/2/2015 | David R Guyer | CEO | Sell | 15,034 | $45.34 | $681,641.56 | |
| 11/13/2014 | A/S Novo | Major Shareholder | Sell | 995,000 | $40.20 | $39,999,000.00 | |
| 11/3/2014 | David R Guyer | CEO | Sell | 15,034 | $39.71 | $597,000.14 | |
| 10/2/2014 | David R Guyer | CEO | Sell | 2,807 | $38.52 | $108,125.64 | |
| 10/2/2014 | Samir Chandrakant Patel | President | Sell | 1,965 | $38.04 | $74,748.60 | |
| 10/1/2014 | David R Guyer | CEO | Sell | 12,227 | $37.30 | $456,067.10 | |
| 10/1/2014 | Samir Chandrakant Patel | President | Sell | 17,676 | $37.28 | $658,961.28 | |
| 9/4/2014 | David R Guyer | CEO | Sell | 1,107 | $38.58 | $42,708.06 | |
| 8/1/2014 | Bruce Peacock | CFO | Sell | 6,191 | $37.78 | $233,895.98 | |
| 8/1/2014 | David R Guyer | CEO | Sell | 13,136 | $37.85 | $497,197.60 | |
| 8/1/2014 | Samir Chandrakant Patel | President | Sell | 18,986 | $37.80 | $717,670.80 | |
| 7/1/2014 | Bruce Peacock | CFO | Sell | 7,739 | $41.07 | $317,840.73 | |
| 7/1/2014 | David R Guyer | CEO | Sell | 15,034 | $41.08 | $617,596.72 | |
| 7/1/2014 | Samir Chandrakant Patel | President | Sell | 18,986 | $41.08 | $779,944.88 | |
| 6/16/2014 | Nicholas Galakatos | Director | Sell | 144,976 | $44.17 | $6,403,589.92 | |
| 6/11/2014 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 211,680 | $45.42 | $9,614,505.60 | |
| 6/4/2014 | Svlsf Iv, Llc | Major Shareholder | Sell | 1,966,935 | $42.54 | $83,673,414.90 | |
| 6/3/2014 | Bruce Peacock | CFO | Sell | 13,931 | $40.12 | $558,911.72 | |
| 6/3/2014 | Svlsf Iv, Llc | Major Shareholder | Sell | 1,865,619 | $40.65 | $75,837,412.35 | |
| 6/2/2014 | David R Guyer | CEO | Sell | 25,417 | $39.92 | $1,014,646.64 | |
| 6/2/2014 | Samir Chandrakant Patel | President | Sell | 27,873 | $39.91 | $1,112,411.43 | |
| 5/30/2014 | Svlsf Iv, Llc | Major Shareholder | Sell | 931,869 | $40.99 | $38,197,310.31 | |
| 5/28/2014 | Svlsf Iv, Llc | Major Shareholder | Sell | 980,127 | $40.19 | $39,391,304.13 | |
| 5/23/2014 | Svlsf Iv, Llc | Major Shareholder | Sell | 330,450 | $38.10 | $12,590,145.00 | |
| 5/13/2014 | Hbm Healthcare Investments (Ca | major shareholder | Sell | 500,000 | $29.75 | $14,875,000.00 | |
| 5/1/2014 | Bruce Peacock | CFO | Sell | 4,643 | $32.43 | $150,572.49 | |
| 5/1/2014 | David Guyer | CEO | Sell | 10,665 | $33.71 | $359,517.15 | |
| 5/1/2014 | Samir Chandrakant Patel | President | Sell | 14,319 | $32.45 | $464,651.55 | |
| 3/24/2014 | Bruce Peacock | CFO | Sell | 6,137 | $34.77 | $213,383.49 | |
| 3/24/2014 | David Guyer | CEO | Sell | 12,027 | $34.53 | $415,292.31 | |
| 3/24/2014 | Samir Chandrakant Patel | President | Sell | 16,876 | $34.54 | $582,897.04 | |
| 2/18/2014 | Svlsf Iv, Llc | major shareholder | Sell | 2,111,364 | $29.61 | $62,517,488.04 | |
| 9/30/2013 | A/S Novo | Insider | Buy | 455,000 | $22.00 | $10,010,000.00 | |
| 9/30/2013 | Hbm Healthcare Investments (Ca | Major Shareholder | Buy | 228,000 | $22.00 | $5,016,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ophthotech Corporation (NASDAQ:OPHT)
Latest Headlines for Ophthotech Corporation (NASDAQ:OPHT)
| Source: |
|
| Date | Headline |
|---|
 | Ophthotech Corporation (OPHT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 12 at 6:56 PM |
 | How Should You Think About Ophthotech Corporation’s (OPHT) Risks?
finance.yahoo.com - October 9 at 8:47 PM |
| $180.65 Million in Sales Expected for Ophthotech Corporation (OPHT) This Quarter
www.americanbankingnews.com - October 4 at 1:24 AM |
| Ophthotech Corp (OPHT) Expected to Post Earnings of $4.31 Per Share
www.americanbankingnews.com - October 3 at 12:28 AM |
 | How is the Age-Related Macular Degeneration Space Faring Now? - Nasdaq
www.nasdaq.com - September 22 at 7:32 AM |
| How is the Age-Related Macular Degeneration Space Faring Now?
finance.yahoo.com - September 22 at 7:32 AM |
| Ophthotech Corporation's (OPHT) Hold Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - September 21 at 1:52 PM |
 | Ophthotech Corp (OPHT) Reports Update on Zimura Complement Programs for Treatment of Eye Diseases
www.streetinsider.com - September 20 at 7:19 AM |
 | BRIEF-Ophthotech gives update on programs for treatment of eye diseases
www.reuters.com - September 20 at 7:19 AM |
| Ophthotech Provides Update on Zimura® Complement Programs for Treatment of Eye Diseases
finance.yahoo.com - September 20 at 7:19 AM |
| Ophthotech Corporation (OPHT) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 17 at 4:46 PM |
| Analysts Issue Forecasts for Ophthotech Corporation's FY2020 Earnings (OPHT)
www.americanbankingnews.com - September 13 at 4:02 PM |
| Roche's Ophthalmology Drug Fails to Meet Primary Endpoint - Nasdaq - Nasdaq
www.nasdaq.com - September 12 at 8:15 AM |
| Roche's Ophthalmology Drug Fails to Meet Primary Endpoint
finance.yahoo.com - September 12 at 8:15 AM |
 | Roche shares decline 1.6% on news that late-stage study missed primary endpoint - MarketWatch
www.marketwatch.com - September 9 at 7:02 AM |
 | Roche lampalizumab flop weighs on Ophthotech, down 10 ... - Seeking Alpha
seekingalpha.com - September 9 at 7:02 AM |
| Roche shares decline 1.6% on news that late-stage study missed primary endpoint
finance.yahoo.com - September 9 at 7:02 AM |
| Why Is Ophthotech (OPHT) Up 7.4% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - August 31 at 8:23 AM |
| Why Is Ophthotech (OPHT) Up 7.4% Since the Last Earnings Report?
finance.yahoo.com - August 30 at 7:39 AM |
| Ophthotech Corporation (OPHT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 23 at 6:46 PM |
| Ophthotech: 3 Strikes And It's Out? - Seeking Alpha
seekingalpha.com - August 22 at 2:31 AM |
| 3 Things In Biotech You Should Learn Today: August 16, 2017
seekingalpha.com - August 18 at 6:51 AM |
| Ophthotech's Fovista Combo Regimen Disappoints in Phase III - Nasdaq
www.nasdaq.com - August 17 at 6:34 AM |
| Ophthotech Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-Related Macular Degeneration
finance.yahoo.com - August 16 at 6:31 AM |
| Ophthotech Corp (OPHT) Phase 3 Trial of Fovista in Wet AMD Didn't Meet Primary Endpoint - StreetInsider.com
www.streetinsider.com - August 15 at 5:50 AM |
| $4.31 EPS Expected for Ophthotech Corporation (NASDAQ:OPHT) This Quarter
www.americanbankingnews.com - August 8 at 10:28 AM |
| Equities Analysts Offer Predictions for Ophthotech Corporation's FY2017 Earnings (NASDAQ:OPHT)
www.americanbankingnews.com - July 31 at 8:15 AM |
| Q3 2017 Earnings Forecast for Ophthotech Corporation Issued By Leerink Swann (NASDAQ:OPHT)
www.americanbankingnews.com - July 31 at 7:41 AM |
| Ophthotech Corporation (NASDAQ:OPHT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 29 at 4:43 PM |
| Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura - Nasdaq
www.nasdaq.com - July 29 at 6:04 AM |
| Ophthotech Corporation (NASDAQ:OPHT) to Post Q4 2017 Earnings of ($0.65) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - July 28 at 3:33 PM |
| BRIEF-Ophthotech reports second quarter 2017 financial and operating results
www.reuters.com - July 27 at 6:07 AM |
| Ophthotech Corp (OPHT) Posts Smaller-than-Expected Q2 Loss
www.streetinsider.com - July 27 at 6:07 AM |
| Ophthotech Corporation 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - July 27 at 6:07 AM |
| Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases
finance.yahoo.com - July 27 at 6:07 AM |
| Ophthotech Reports Second Quarter 2017 Financial and Operating Results
finance.yahoo.com - July 27 at 6:07 AM |
| Ophthotech reports 2Q loss
finance.yahoo.com - July 27 at 6:07 AM |
| Edited Transcript of OPHT earnings conference call or presentation 26-Jul-17 12:00pm GMT
finance.yahoo.com - July 27 at 6:07 AM |
| Ophthotech Corporation (OPHT) Issues Earnings Results
www.americanbankingnews.com - July 26 at 11:44 AM |
 | Ophthotech Corporation to Report Second Quarter 2017 Financial ... - Business Wire (press release)
www.businesswire.com - July 22 at 7:20 AM |
| Ophthotech Corporation to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, July 26, 2017
finance.yahoo.com - July 22 at 7:20 AM |
| Ophthotech Corporation (OPHT) Expected to Post Quarterly Sales of $1.44 Million
www.americanbankingnews.com - July 21 at 9:08 PM |
| Analysts Expect Ophthotech Corp (OPHT) to Post -$1.09 Earnings Per Share
www.americanbankingnews.com - July 19 at 8:53 AM |
| Global $8.91 Billion Aptamers (Nucleic Acid & Peptide) Market 2014-2017 - Forecasts to 2025 - Research and Markets
www.businesswire.com - July 14 at 7:12 AM |
| Ophthotech Corporation (NASDAQ:OPHT) SVP Sells $13,207.02 in Stock
www.americanbankingnews.com - July 5 at 8:32 PM |
| Ophthotech Corporation (OPHT) CEO Sells $20,196.24 in Stock
www.americanbankingnews.com - July 5 at 8:32 PM |
| Insider Selling: Ophthotech Corporation (NASDAQ:OPHT) Chairman Sells 17,678 Shares of Stock
www.americanbankingnews.com - July 5 at 8:08 PM |
| Ophthotech Corporation (OPHT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 4 at 5:23 PM |
 | Biotech Stocks on Investors' Radar -- Ophthotech, Pacific Biosciences of California, PTC Therapeutics, and Portola ... - PR Newswire (press release)
www.prnewswire.com - May 24 at 10:15 AM |
| BRIEF-David Shaw reports a 5 pct passive stake in Ophthotech Corp as of May 11 ...
www.reuters.com - May 22 at 6:15 PM |
Ophthotech Corporation (OPHT) Chart for Saturday, October, 21, 2017
